Dr Carr brings a wealth of experience in the biotech industry to the role. As CEO of Amersham Biosciences and a Director of Amersham plc, Dr Carr played a key role in growing the Life Science Research and Bio-separations business units until the successful acquisition of Amersham by GE Healthcare in 2004. Dr Carr is currently a Non-executive Director and Chairman of several European private equity funded companies and has been involved in raising finance and execution of third party deals.
“BAC’s technology has important proven applications in the manufacture of bio molecules which have now been adopted by many of the world’s leading bio-pharmaceutical companies, and I am delighted to be invited to lead the Supervisory Board at this exciting stage of the Company’s growth and selection of strategic options” commented Dr Carr.
Welcoming Dr Carr to the Supervisory Board, Laurens Sierkstra, CEO of BAC, said: “It’s a great start to 2008 to have Andrew join us and bring his extensive experience in the biotech industry. Our CaptureSelect® technology has met with considerable success and offers huge potential to the industry. I look forward to working with Dr Carr to drive the Company’s growth and development in both the industrial bioprocessing and laboratory products markets.”
Dr Carr is currently Chairman of deltaDOT Ltd and Teraview Ltd, a Director of SciBridge Ltd, and an advisor to SpinX-Technologies SA. He is also a member of the Imperial Innovations investment advisory group. Dr Carr has a PhD in Zoology from the University of Nottingham. About BAC BAC BV – The Bio Affinity Company – offers a wide range of products and services for affinity purification of biological materials from complex media. The Company’s proprietary CaptureSelect® affinity ligands, based on Camelid single chain antibody fragments, have been proven to be suitable in a wide range of biological applications including Life Science Research and Biomanufacturing.
CaptureSelect® ligand technology is based on selection of single chain antibody fragments with desirable chromatographic characteristics including robustness, high specificity and flexibility. Suitable ligands are cloned and expressed in high-titers through an animal-free Saccharomyces cerevisiae-based process that delivers a highly competitive cost of goods.
BAC BV was established in 1995 as a Unilever subsidiary. Currently the Company employs 28 people with an R&D laboratory facility in Vlaardingen and a state-of-the-art ISO 9001 certified manufacturing plant in Naarden, the Netherlands. For more information about BAC, visit our website at www.bac.nl. For more information about CaptureSelect® products, visit our website at www.captureselect.com
Media enquiries: Kathryn Robertson, College Hill kathryn.robertson@collegehill.com Tel: +44 (0)1260 296 506
